美国Achaogen
2002年，罗姆斯伯格的实验室刚开始获得以上结果时，他就发现了一种潜在的药物——能和抗生素一起服用的小分子药物，该药物可以阻止LexA受到剪切。他与两个合伙人毫不费力就筹集到1500万美元，开办了一家名叫Achaogen的公司(“Achao”的意思是“抵制混乱”——并由一位投资者添加上“gen”，因为名称中具有这个后缀的公司，其发展往往会一帆风顺)。
Achaogen (a-KAY-o-jen) develops small molecule therapeutics to treat multi-drug resistant bacterial infections, a serious unmet medical need causing hundreds of thousands of deaths worldwide each year.

Achaogen is developing next-generation aminoglycosides: “neoglycosides”— a designation that reflects their lineage and conveys their novelty. Achaogen’s lead neoglycosides display broad-spectrum activity against many resistant bacteria that cause systemic infections, including K. pneumoniae, E. coli and MRSA.

Our world-class team has led or participated in the development of several approved and/or late-stage antibacterial compounds, and our scientific advisors include U.S. and European thought leaders in antimicrobial resistance and drug development. We focus these resources on the tasks of compound discovery, lead optimization, and early-stage clinical trials, while leveraging external resources worldwide for screening and hit generation and for later-stage clinical work. This maximizes our capital efficiency, minimizing infrastructure costs while mitigating the risks and costs of late phase trials.

Our state-of-the-art research facility is located on the shores of the San Francisco Bay, five minutes from the San Francisco International Airport, and only fifteen minutes from downtown San Francisco.